Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials

Efficacy and safety of selinexor in recurrent glioblastoma.

(2019) Andrew B. Lassman et al.   JOURNAL OF CLINICAL ONCOLOGY

Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP)

(2019) Rick Kapur et al.   PLATELETS

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

(2019) Ajai Chari et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma

(2018) Ujjawal H. Gandhi et al.   Clinical Lymphoma Myeloma & Leukemia

Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma

(2018) Dan T. Vogl et al.   JOURNAL OF CLINICAL ONCOLOGY

Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study

(2018) Philippe Moreau et al.   LANCET ONCOLOGY

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network

(2018) Heinz Ludwig et al.   LEUKEMIA

Global Burden of Multiple Myeloma

(2018) Andrew J. Cowan et al.   JAMA Oncology

Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma

(2018) Nizar J. Bahlis et al.   BLOOD

Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement

(2017) Sabela Bobillo et al.   HAEMATOLOGICA

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial

(2017) Brian G M Durie et al.   LANCET

Promising activity of selinexor in the treatment of a patient with refractory diffuse large B-cell lymphoma and central nervous system involvement

(2017) Sabela Bobillo et al.   HAEMATOLOGICA

2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

(2016) F. Roila et al.   ANNALS OF ONCOLOGY

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

(2016) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies

(2016) Z A Hing et al.   LEUKEMIA

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

(2016) Jesús F San-Miguel et al.   Lancet Haematology

Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets

(2015) K. Sehgal et al.   BLOOD

Real-world treatment patterns, comorbidities, and disease-related complications in patients with multiple myeloma in the United States

(2015) Xue Song et al.   CURRENT MEDICAL RESEARCH AND OPINION

Nucleo-cytoplasmic transport as a therapeutic target of cancer

(2014) Giovanni Luca Gravina et al.   Journal of Hematology & Oncology

Atomic basis of CRM1-cargo recognition, release and inhibition

(2014) Ho Yee Joyce Fung et al.   SEMINARS IN CANCER BIOLOGY

Genome-wide studies in multiple myeloma identify XPO1/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276

(2013) J Schmidt et al.   LEUKEMIA

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

(2013) Y-T Tai et al.   LEUKEMIA

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

(2012) D. S. Siegel et al.   BLOOD

Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia

(2012) R. Lapalombella et al.   BLOOD

Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells

(2012) J Etchin et al.   LEUKEMIA

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma

(2009) P. Richardson et al.   BLOOD

Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial

(2009) Rudolph M. Navari et al.   SUPPORTIVE CARE IN CANCER